शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

INNOVACAPNSEInnova Captab Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 20 May, 2025 · 12:15 IST

Innova Captab Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

INNOVACAP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.2%Reaction day
₹922.00
prior close
₹914.15
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-1.1%-0.1% vs market
Pharmaceuticals peers, median of 149sector-1.0%-0.1% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.1
10m
+0.2
15m
-0.2
30m
-0.0
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.2-1.1-0.1-1.0-0.1
Next day
-4.0-0.3-3.7-0.3-3.7
2d
-5.7-0.4-5.3-0.1-5.7
3d
-3.4+0.3-3.6-0.4-2.9
4d
-5.6+0.8-6.5+0.0-5.6
5d
-6.3+0.7-7.0-0.3-6.0
1w
-5.8+1.4-7.3+0.8-6.6
15d
-6.5+4.7-11.2+0.3-6.8
1m
-8.0+0.7-8.7-2.3-5.8
2m
-2.0+6.4-8.4+2.2-4.3
3m
-2.4+2.7-5.0-1.4-1.0
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Innova Captab Limited reported audited consolidated revenue from operations of ₹12,436.76 million for FY25, up about 15% from ₹10,813.05 million in FY24. Consolidated net profit jumped roughly 36% to ₹1,282.58 million (FY24: ₹943.45 million), translating to EPS of ₹22.41 versus ₹18.66. Q4 FY25 revenue grew to ₹3,147.41 million (Q4 FY24: ₹2,626.34 million), with PAT of ₹295.73 million. On a standalone basis, FY25 revenue rose about 11% to ₹9,580.61 million and PAT climbed around 31% to ₹894.70 million. Statutory auditor B S R & Co. LLP issued an unmodified (clean) opinion on both standalone and consolidated results.

Likely market impact

Strong profit growth on healthy revenue expansion and an unqualified auditor opinion is positive for shareholders, signalling solid operating performance. The company also approved the 21st AGM notice and shifted its registered office within Vashi, both routine administrative actions with no material financial impact.

By the numbersConsolidated · Q4 FY25 vs Q4 FY24
Q4 FY25Q4 FY24Change
Revenue₹314.7 Cr₹262.6 Cr+19.8%
Operating profit₹35.93 Cr₹33.86 Cr+6.1%
Profit after tax₹29.57 Cr₹28.72 Cr+3.0%
EBITDA margin15.2%14.5%+0.7 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.